AbbVie (ABBV) Invested Capital (2012 - 2026)

AbbVie has disclosed Invested Capital across 15 years of filings, most recently posting -$6.7 billion for Q1 2026.

• In Q1 2026, Invested Capital fell 227.24% year-over-year to -$6.7 billion; the TTM figure through Mar 2026 stood at -$6.7 billion (down 227.24% YoY), while the FY2025 annual figure was $61.7 billion, down 12.45% from the prior year.
• Invested Capital eased to -$6.7 billion in Q1 2026, from $61.7 billion in the prior quarter.
• Over the last five years, Invested Capital for ABBV reached as high as $80.6 billion in Q4 2022 and fell as low as -$6.7 billion in Q1 2026.
• The 5-year median for Invested Capital is $16.1 billion (2023), against an average of $24.9 billion.
• Annual changes were most pronounced in 2024 — Invested Capital surged 50.47% — and 2026, when it sank 227.24%.
• A 5-year view of Invested Capital shows it stood at $80.6 billion in 2022, then retreated by 13.38% to $69.8 billion in 2023, then rose by 1.04% to $70.5 billion in 2024, then slipped by 12.45% to $61.7 billion in 2025, then plunged by 110.78% to -$6.7 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered -$6.7 billion, $61.7 billion, and -$660.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.